RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

RC48: 2.5 mg/kg, intravenous infusion, on day 1, every 3 weeks (Q3W);

Adebrelimab：1200 mg, intravenous infusion, on day 1, every 3 weeks (Q3W);

Apatinib: 250mg, oral administration, once daily (qd), every 3 weeks (Q3W);

S-1：For patients with a body surface area (BSA) ≤1.5m², use 50mg each time; for patients with BSA \>1.5m², use 60mg each time, oral administration, twice daily (bid), on days 1-14, every 3 weeks (Q3W);